US Generic Drug Spending Declines In A New Development – IQVIA Report

Generic drug spending declined in the US by $5.5bn in 2017 after growing in 2013-2016, pointing to the challenging generic drug dynamics in the US. Volume share data on marketed biosimilars shows impact of insurer control.

PillChart_1200x675

More from Drug Pricing

More from Scrip